LAMP1 and congenital rubella syndrome: By contrast, in vitro studies with a BCMA‐targeting BiTe® construct BI836909 (AMG420) showed dose‐dependent T cell degranulation (CD107a expression) and ≥1000 fold increase of CRS associated cytokines in PBMC culture supernatants [11].